Glandore managing director Michael Kelly has increased his stake in Cathal Friel’s Poolbeg Pharma to nearly 5 per cent, new stock exchange filings show.
Mr Kelly now holds a 4.8 per cent stake in the company having bought up 5.8 million shares in mid-March, an acquisition which has just been disclosed to the markets.
The purchase of the shares would have cost him just under £600,000 (€699,000) at the company’s price at the time of around 10 pence.
His total stake in Poolbeg is now worth around £2.8 million, as its shares have risen in price to closer to 12 pence per share. The recent acquisition has made him the second largest individual shareholder in Poolbeg, after its founder, Mr Friel.
The great Guinness shortage has lessons for Diageo
Ireland has won the corporation tax game for now, but will that last?
Corkman leading €11bn development of Battersea Power Station in London: ‘We’ve created a place to live, work and play’
Elf doors, carriage rides and boat cruises: Christmas in Ireland’s five-star hotels
Mr Kelly is the managing director of Glandore, a company that offers co-working hubs for tech companies in Dublin and Belfast. Its clients have included Facebook, Dropbox, Twitter, Yelp, Rapid7 and Bloomberg, according to Mr Kelly’s own LinkedIn page.
Glandore also owns Suesey Street restaurant and the No 25 private dining facility, both on Fitzwilliam Place in Dublin.
Poolbeg Pharma was founded as a spin-off from Mr Friel’s company Open Orphan, now called hVivo, and floated on the London stock exchange’s AIM market in 2021. It focuses on developing new drugs to combat infectious diseases.
Mr Friel recently stepped down as chief executive to be replaced by Jeremy Skillington, and now serves as executive chairman.
The company also hired a number of executives from Amryt Pharma, another Friel-related company which was sold last year for nearly $1.5 billion. The hires included Laura Maher, David Allmond and John McEvoy, a move Mr Friel described as “getting the band back together”.
The company’s board of advisers also includes Luke O’Neill, professor of biochemistry in Trinity College’s school of biochemistry.
In a recent interview with the Business Post, Mr Skillington said the company could reach a €1 billion valuation.
Poolbeg has yet to generate any revenue, but had a cash balance of £14.1 million on June 30th last, down from £16.2 million at the end of 2022, it revealed in half-year results published in June.
- Sign up for Business push alerts and have the best news, analysis and comment delivered directly to your phone
- Find The Irish Times on WhatsApp and stay up to date
- Our Inside Business podcast is published weekly – Find the latest episode here
